Success Metrics

Clinical Success Rate

62.5%

Based on 5 completed trials

Completion Rate

63%(5/8)

Active Trials

1(8%)

Results Posted

80%(4 trials)

Terminated

3(23%)

Phase Distribution

Ph phase_3

15%

Ph phase_1

Ph phase_4

46%

Ph phase_2

31%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution13 total trials

Phase 1Safety & dosage

1(7.7%)

Phase 2Efficacy & side effects

4(30.8%)

Phase 3Large-scale testing

2(15.4%)

Phase 4Post-market surveillance

6(46.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(5)

Terminated(3)

Other(2)

Detailed Status

Completed5

Terminated3

Not yet recruiting2

unknown2

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

62.5%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (7.7%)

Phase 24 (30.8%)

Phase 32 (15.4%)

Phase 46 (46.2%)

Trials by Status

not_yet_recruiting215%

active_not_recruiting18%

completed538%

terminated323%

unknown215%

Recent Activity

1 active trials

Showing 5 of 13

active_not_recruitingphase_2

BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

NCT05156710

not_yet_recruitingphase_4

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

NCT07352566

not_yet_recruitingphase_2

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898

terminatedphase_4

Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol

NCT00866684

terminatedphase_2

Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid

NCT05263505

View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials

NCT05156710Phase 2

BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

Active Not Recruiting

NCT07352566Phase 4

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Not Yet Recruiting

NCT07138898Phase 2

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Not Yet Recruiting

NCT00866684Phase 4

Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol

Terminated

NCT05263505Phase 2

Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid

Terminated

NCT04424602Phase 4

Comparison between2 Drugs in Lupus Nephritis

Completed

NCT04945096Phase 3

Outcomes of Patients After Allo-HSCT With Decitabine and NAC

Unknown

NCT02152345Phase 4

Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients

Completed

NCT01490723Phase 2

Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

Completed

NCT02167958Phase 1

Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

Completed

NCT00262132Phase 3

Mycophenolate for Pulmonary Sarcoidosis

Terminated

NCT02453867Phase 4

Efficacy and Safety of a Reduced Immunosuppression vs. Standard Triple Therapy in Senior Renal Transplant Recipients

Unknown

NCT02683291Phase 4

Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients

Completed

All 13 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 13